- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Silexion erweitert Dual-Route-Strategie für KRAS-Krebstherapie | - | Investing.com Deutsch | ||
| Fr | Silexion advances dual-route strategy for KRAS cancer therapy | 2 | Investing.com | ||
| Fr | Silexion Therapeutics Corp: Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data | 100 | GlobeNewswire (Europe) | Grand Cayman, Cayman Islands, March 28, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference... ► Artikel lesen | |
| SILEXION THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Fr | Silexion Therapeutics Corp - 8-K, Current Report | 1 | SEC Filings | ||
| Do | Silexion Therapeutics Corp - S-1/A, General form for registration of securities | 1 | SEC Filings | ||
| 18.03. | Silexion Therapeutics Corp - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 18.03. | Silexion Therapeutics GAAP EPS of -$26.36 | 5 | Seeking Alpha | ||
| 18.03. | Silexion Therapeutics Corp: Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update | 966 | GlobeNewswire (Europe) | Grand Cayman, Cayman Islands, March 18, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference... ► Artikel lesen | |
| 18.03. | Silexion Therapeutics Corp - 10-K, Annual Report | 1 | SEC Filings | ||
| 14.03. | Silexion Therapeutics Corp - 8-K, Current Report | 2 | SEC Filings | ||
| 05.03. | Silexion Therapeutics' Preclinical Cancer Candidate Shows Tumor Reduction For Pancreatic Cancer | 3 | Benzinga.com | ||
| 05.03. | Silexion Therapeutics Corp: Silexion Therapeutics Reports Groundbreaking Positive Initial Data from Systemic Administration of SIL204 in Orthotopic Pancreatic Cancer Models | 153 | GlobeNewswire (Europe) | Grand Cayman, Cayman Islands, March 05, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference... ► Artikel lesen | |
| 05.03. | Silexion Therapeutics Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 25.02. | Silexion Therapeutics Corp: Silexion Therapeutics Announces Completion of Initial Study in Orthotopic Pancreatic Cancer Models Evaluating Systemic Administration of SIL-204 | 133 | GlobeNewswire (Europe) | Grand Cayman, Cayman Islands, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference... ► Artikel lesen | |
| 12.02. | Silexion Therapeutics Corp - S-1, General form for registration of securities | 3 | SEC Filings | ||
| 30.01. | Pre-market Movers: China Liberal Education, CARGO Therapeutics, Tectonic Therapeutic, Silexion Therapeutics, Banzai International | 1.366 | AFX News | SANDY SPRINGS (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.35 A.M. ET).In the Green Tectonic Therapeutic, Inc. (TECX) is up over... ► Artikel lesen | |
| 29.01. | Silexion Therapeutics announces exercise of warrants for $3.3M gross proceeds | 15 | Seeking Alpha | ||
| 29.01. | Silexion Therapeutics Corp: Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds | 5 | GlobeNewswire (USA) | ||
| 29.01. | HotStocks USA: +60 % bei Silexion Therapeutics | 14 | stock3.com | ||
| 29.01. | Pre-market Movers: Silexion Therapeutics, Zentalis Pharmaceuticals, 60 Degrees Pharmaceuticals, Manhattan Associates, Nextracker | 469 | AFX News | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.30 A.M. ET).In the Green Silexion Therapeutics Corp (SLXN) is up over 65%... ► Artikel lesen |
Seite:
1 2 3 Weiter >>
48 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVAVAX | 5,998 | -7,38 % | Novavax Aktie: Dunkelheit vor dem Sturm? | Der Biotechnologiekonzern verzeichnet erhebliche Kursverluste, setzt jedoch auf die Kooperation mit Sanofi als wichtigen Baustein für zukünftige Ertragsquellen und Kostenoptimierung. Die Novavax-Aktie... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 0,546 | -10,34 % | Palatin Techs Aktie: Positive Signale setzen! | Biotechnologieunternehmen erreicht wichtigen regulatorischen Durchbruch mit oralem Wirkstoff gegen genetisch bedingte Fettleibigkeit und verzeichnet Kursanstieg Palatin Technologies, Inc. (NYSE American:... ► Artikel lesen | |
| TREVENA | 0,153 | 0,00 % | Delisting of Securities of Patria Latin American Opportunity Acquisition Corp.; Trevena, Inc.; Seelos Therapeutics, Inc.; DP Cap Acquisition Corp I; Chain Bridge I; Qomolangma Acquisition Corp.; Gaucho Group Holdings, Inc. ... | NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the Class A Ordinary Shares, unit, and warrant of Patria Latin American Opportunity Acquisition... ► Artikel lesen | |
| SORRENTO THERAPEUTICS | - | - | Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to April 14, 2025 | US Bankruptcy Court for the Southern District of Texas issued an order to extend the lock-up period on the Scilex Dividend Stock, previously distributed by Sorrento, to April 14, 2025.Accordingly... ► Artikel lesen | |
| VERASTEM | 5,450 | -4,39 % | Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates | BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced business updates and reported... ► Artikel lesen | |
| BIOLINERX | 3,283 | -100,00 % | BioLineRx Ltd.: BioLineRx Reports 2024 Financial Results and Provides Corporate Update | - Reports meaningful progress in the evaluation of assets for potential in-licensing and development in the areas of oncology and rare diseases -
- Executed license... ► Artikel lesen | |
| TENAX THERAPEUTICS | 2,770 | -100,00 % | Tenax Therapeutics, Inc.: Tenax Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update | Successfully Completed Private Placements with Aggregate Gross Proceeds of Approximately $125 Million to Support Advancement of Two Registrational Studies for TNX-103 in PH-HFpEF and Fund Operations... ► Artikel lesen | |
| QUANTUM-SI | 1,195 | 0,00 % | Quantum-Si begins global shipment of Platinum Pro sequencer | ||
| LEAP THERAPEUTICS | 0,304 | +7,04 % | Leap Therapeutics, Inc.: Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results | Leap to host a conference call to present updated CRC clinical data today, March 26, 2025, at 8:00 a.m. ET
CAMBRIDGE, Mass., March 26, 2025 /PRNewswire/ --... ► Artikel lesen | |
| TRANSCODE THERAPEUTICS | 0,491 | 0,00 % | TransCode Therapeutics, Inc.: TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138 | First patient in Cohort four has been treated with TTX-MC138
Ten patients have been treated with TTX-MC138 at escalating dose levels
Additional patients being... ► Artikel lesen | |
| PSYENCE BIOMEDICAL | 0,635 | 0,00 % | Corporate Update: Psyence Biomedical Ltd Redefines Psychedelic Medicine with a Multi-Asset Strategy, Advancing Clinical Trials and Scalable Manufacturing | New York, New York--(Newsfile Corp. - March 31, 2025) - Psyence Biomedical Ltd. (NASDAQ: PBM) ("Psyence BioMed" or the "Company") releases the following update:Dear Shareholders and Future Investors:At... ► Artikel lesen | |
| MINK THERAPEUTICS | 9,050 | 0,00 % | MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress | NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf invariant natural... ► Artikel lesen | |
| TEMPUS AI | 48,240 | 0,00 % | Why Tempus AI Inc. (TEM) Crashed On Wednesday? | ||
| QIAGEN | 36,675 | -0,34 % | Biotech Report: Sektor unter Druck - Evotec verlieren, Qiagen behauptet | (shareribs.com) Frankfurt / New York 26.03.2025 - Biotechwerte tendierten im deutschen Handel schwächer, lediglich 4SC konnte leichte Kursgewinne verbuchen. An der Wall Street rutschte der Sektor ab.... ► Artikel lesen | |
| BIONTECH | 82,45 | -5,12 % | Übernahmespekulationen und Kaufempfehlungen: Bayer, BioNTech, Evotec, BioNxt Solutions Aktie | Während bei Evotec derzeit die Übernahmespekulationen pausieren, nehmen sie bei BioNxt Solutions Fahrt auf. Das Unternehmen will in den kommenden 60 Tagen wichtige Meilensteine auf dem Weg zur Vermarktung... ► Artikel lesen |
Das Unternehmen SILEXION THERAPEUTICS CORP kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 1,090 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SILEXION THERAPEUTICS CORP finden Sie auf Wallstreet Online.
